Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Single-Blind Study Determining the Efficacy of Polypodium Leucotomos Extract Supplement in Decreasing Ultraviolet A (UVA) Premutagenic and Photoaging Markers (Heliocare)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified June 2008 by University of Miami.
Recruitment status was:  Active, not recruiting
Information provided by:
University of Miami Identifier:
First received: August 24, 2007
Last updated: October 18, 2010
Last verified: June 2008

With this study we will like to determine if taking a dose of the study medication, called Polypodium leucotomos (PL), prevents some of the changes in the skin caused by the adverse effects of UVA, a type of ultraviolet light. Ultraviolet light is a form of radiation which is not visible to the human eye. The sun produces different types of ultraviolet radiation, and UVA is one of them. More than 95% of the solar UV energy that reaches our skin is from the UVA type. UVA penetrates cloud cover and glass windows.

PL extract comes from a tropical fern plant grown in Central and South America, and it is a dietary supplement available in the US. No side effects have been reported with Polypodium leucotomos extract since becoming commercially available in 1982. Also, PL extract was approved for oral use by the Institutional Review Board of The Massachusetts General Hospital, Boston, for studies by Harvard Medical School faculty in human volunteers that were carried out for a period of two years, using artificial light and sunlight as ultraviolet sources.

This is an investigator-blinded study, which means that the doctor evaluating you will not know if you are receiving the study medication or not. Another doctor will be supplying you with the medication and discussing any problems that you may have with the medication.

You will be assigned to one of the two treatment groups. The group will be assigned by chance and you will have a one in two chances of receiving either the study medication or no treatment.

Condition Intervention Phase
Skin Abnormalities
Drug: Polypodium leucotomos
Other: No Treatment
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Investigator)
Primary Purpose: Basic Science
Official Title: Single-Blind Study Determining the Efficacy of Polypodium Leucotomos Extract Supplement in Decreasing UVA Premutagenic and Photoaging Markers

Resource links provided by NLM:

Further study details as provided by University of Miami:

Primary Outcome Measures:
  • H&E study of skin biopsy sample taken from final visit [ Time Frame: 24 hours after Ultraviolet A treatment ]
  • PCR determination of common deletion in DNA of skin biopsy sample taken from final visit [ Time Frame: 24 hours after Ultraviolet A treatment ]
  • 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxo-dG) quantification in skin biopsy sample taken from final visit [ Time Frame: 24 hours after Ultraviolet A treatment ]

Estimated Enrollment: 10
Study Start Date: August 2007
Estimated Study Completion Date: May 2009
Estimated Primary Completion Date: May 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Subject is given a 7.5 mg/kg dose of Polypodium leucotomos.
Drug: Polypodium leucotomos
Subject is given a 7.5 mg/kg oral dose of Polypodium leucotomos during Baseline visit, and again at 8 hours and 2 hours before the Follow-up visit #2.
Other Name: Heliocare
No Intervention: 2
Subject is not given any treatment.
Other: No Treatment
Patient is not given any treatment.

  Show Detailed Description


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy subjects,
  • 18 years of age or older,
  • with Fitzpatrick skin types II and III.

Exclusion Criteria:

  • Pregnancy
  • Personal history of skin cancer
  • History of abnormal photosensitivity
  • Smokers
  • Patients with history or being exposed to other forms of radiation (other than sunlight)
  • History or current exposure to asbestos
  • Patients taking any drug that might alter the response of skin to UVR (including, but are not limited to, doxycycline, sulfas, psoralens, and amiodarone)
  • Patients unable to undergo skin biopsies
  • History of abnormal scarring
  • History of adverse reaction to local anesthesia
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00520910

United States, Florida
University of Miami Skin Research Group Office
Miami, Florida, United States, 33136
Sponsors and Collaborators
University of Miami
Principal Investigator: Brian Berman, M.D., Ph.D. University of Miami, Department of Dermatology and Cutaneous Surgery
  More Information

Additional Information:

Responsible Party: Brian Berman, M.D., Ph.D., University of Miami Miller School of Medicine Identifier: NCT00520910     History of Changes
Other Study ID Numbers: 20070203
Study First Received: August 24, 2007
Last Updated: October 18, 2010

Keywords provided by University of Miami:
Polypodium leucotomos, Ultraviolet Rays, Heliocare, calaguala, anapsos
Skin Aging and Damage

Additional relevant MeSH terms:
Skin Abnormalities
Congenital Abnormalities
Skin Diseases processed this record on May 22, 2017